The largest database of trusted experimental protocols

10 protocols using l 745870

1

Signaling Pathway Antibodies and Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
PREX1 [D8O8D] rabbit monoclonal, PTEN [138G6] rabbit monoclonal, Phospho-PAK1 (Ser144)/PAK2 (Ser141) rabbit polyclonal, PAK2 [3B5] mouse monoclonal were purchased from Cell Signaling (Danvers, MA, USA). GAPDH [6C5] mouse monoclonal and CDC42 [M152] mouse monoclonal were purchased from Abcam (Cambridge, MA, USA). Phospho-PKCι (T555)/PKCλ (T563) rabbit polyclonal was purchased from Invitrogen (Carlsbad, CA, USA) and PKCι mouse monoclonal from (BD Transduction Laboratories (Mississauga, ON, Canada). Sox2 mouse monoclonal was from R&D Systems (Minneapolis MN, USA). Rac1[23A8] mouse monoclonal, anti-Flag M2 mouse monoclonal and Stem121 mouse monoclonal were purchased from Millipore (Temecula, CA, USA), Sigma-Aldrich (Oakville, ON, Canada) and StemCells Inc. (Newark, CA, USA), respectively. Human brain cerebral cortex protein medley was purchased from Clontech (Mountain View, CA, USA). The following inhibitors were used in the study: gallein (Santa Cruz Biotechnology, CA, USA), BKM120 (Sigma-Aldrich, Oakville, ON, Canada); trichostatin A (Cayman Chemical Company, Ann Arbor, MI, USA); haloperidol, L-741,626 and L-745,870 (Tocris Bioscience, Minneapolis, MN, USA).
+ Open protocol
+ Expand
2

Dopamine Receptor Agonist and Antagonist Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols
The DR1 agonist SKF-81297 (1 μM), the D2-like receptor agonist quinpirole (10 μM), the selective DR3 agonist pramipexole (10 μM), the DR4 agonist PD-168077 (200 nM), the selective DR4 antagonist L-745870 (500 nM), the dopamine (200 μM), the n-methy-d-aspartate (NMDA) receptor antagonist D-AP5 (50 μM) and CCH (5 μM) were purchased from Tocris Bioscience. Stock solutions, at thousand times the final concentration, were made up in water or in DMSO, and stored in individual aliquots at 20°C. Final solutions were prepared freshly on the day of the experiment. Drugs were applied to the recording ACSF 15 min after steady-state γ power was reached. The dead volume and bath volume was kept such that final concentration was reached in the bath in about 5 min.
+ Open protocol
+ Expand
3

Insulin Receptor Antibody Immunoblotting

Check if the same lab product or an alternative is used in the 5 most similar protocols
Insulin receptor antibody is polyconal rabbit antihuman antipeptide (Santa Cruz Biotechnology, Santa Cruz, CA).18 Goat polyclonal p‐insulin Rβ antibody (Santa Cruz Biotechnology) was used as the phosphorylated insulin receptor antibody. RPT cells were treated with vehicle (dH2O), a D4 receptor agonist (PD168077; Tocris Cookson Ltd, Bristol, UK),19 or ABT724 (2‐[(4‐pyridin‐2‐ylpiperazin‐1‐yl)methyl]‐1H‐benzimidazole trihydrochloride; Sigma‐Aldrich, St. Louis, MO) or a D4 receptor antagonist20 (L‐745870 [Tocris] or L750667 [Sigma‐Aldrich]) at the indicated concentrations and times as described previously.21 Transblots were probed with insulin receptor antibody (1:400). The amount of protein transferred onto membranes was determined by immunoblotting for α‐actin.
+ Open protocol
+ Expand
4

Pharmacological Modulation of Neurotransmission

Check if the same lab product or an alternative is used in the 5 most similar protocols
Carbachol (carbamylcholine chloride), kainate (kainic acid monohydrate), quinpirole, (+)- sulpiride, (+)-SKF-38393, PD168,077, carbenoxolone disodium salt, picrotoxin were purchased from Sigma (Sigma-Aldrich, Buchs, Switzerland); SYM2206 and L745.870 were from Tocris Bioscience (Bristol, UK); AP-5 (DL-2-amino-5-phosphopentanoic acid) was from Alexis Biochemicals (San Diego, CA); R(+)-SCH23390 HCl was from Research Biochemical International (Sigma-Aldrich, Buchs, Switzerland).
+ Open protocol
+ Expand
5

Retinal Dopamine Receptor Pharmacology

Check if the same lab product or an alternative is used in the 5 most similar protocols
(–)-Sulpiride, (–)-eticlopride, and L-745,870 were purchased from Tocris Bioscience (Minneapolis, MN). Eticlopride and L-745,870 were dissolved in physiological saline (0.9% NaCl). Sulpiride was dissolved in dimethylsulphoxide (DMSO) and diluted 50-fold in physiological saline. The drug solutions were applied to the bathing solution using calibrated syringe pumps (Razel Scientific Instruments). The final concentration of DMSO at the retina for the sulpiride solution was approximately 0.02%. Drugs were bath applied for ~10 min to ensure stable responses before effects were examined. Only one cell was studied in each retina to avoid possible residual drug effects.
+ Open protocol
+ Expand
6

Monitoring Dopamine and Glutamate Dynamics in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Experiments were performed 36 hours after probe implantation in freely moving mice. Ringer’s solution (147 mM NaCl, 4 mM KCl, and 2.2 mM CaCl2) was pumped through the probes at a constant rate of 1 μl/min. After 30 min of equilibration, samples were collected every 10 min (DA analysis) or 20 min (GLU analysis) for 80 min. The indicated doses of (+)-METH-HCl (NIDA Pharmacy) or (−)-cocaine-HCl (NIDA Pharmacy) were administered intraperitoneally using saline (10 ml/kg) (0.9% NaCl) as a vehicle. After the systemic administration, samples were collected every 10 min (DA analysis) or 20 min (GLU analysis) for 90 or 120 min, respectively. Where indicated, vehicle (saline), the D1 receptor antagonist SCH23390 (1 mg/kg; Tocris), or the D4 receptor antagonist L-745,870 (1 mg/kg; Tocris) was systemically administered (10 ml/kg, intraperitoneally) 10 min before METH or cocaine treatment. DA content in the dialyzate fractions was measured by high-performance liquid chromatography (HPLC) coupled to a coulometric detector (5200a Coulochem III, ESA). GLU was measured by HPLC coupled to a GLU oxidase enzyme reactor and electrochemical detector (Eicom Corporation).
+ Open protocol
+ Expand
7

Pharmacological Reagents Inventory

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cocaine HCl was obtained from the National Institute on Drug Abuse. NBQX, CPP, sulpiride, quinpirole, sumatriptan, GBR12783, tamoxetine, citalopram, 5-HT, and L-745870 were purchased from Tocris. Gabazine, kynurenic acid (sodium salt), and WAY 100635 were obtained from Abcam. All other chemicals were from Sigma.
+ Open protocol
+ Expand
8

Pharmacological Reagents Inventory

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cocaine HCl was obtained from the National Institute on Drug Abuse. NBQX, CPP, sulpiride, quinpirole, sumatriptan, GBR12783, tamoxetine, citalopram, 5-HT, and L-745870 were purchased from Tocris. Gabazine, kynurenic acid (sodium salt), and WAY 100635 were obtained from Abcam. All other chemicals were from Sigma.
+ Open protocol
+ Expand
9

Dopamine Receptor Modulation of Motor Activity

Check if the same lab product or an alternative is used in the 5 most similar protocols
Dopamine hydrochloride (Sigma-Aldrich, Inc., St. Louis, MO) was bath applied in separate experiments at 1 µM, 3 µM, 10 µM, 30 µM, 100 µM, and 300 µM to determine dose-dependent effects on motor activity. The receptor-selective agonists we used included SKF 81297 for D1-like receptors (10–50 µM; Tocris, Minneapolis, MN); quinpirole for D2-like receptors (10–50 µM; Tocris); and the D1/D2 receptor co-agonist SKF 83959 (10–50 µM; Tocris). For dopamine receptor antagonists we used the D1-like antagonist SCH-23390 (10 µM; Tocris); the D2-like antagonists sulpiride (20 µM) and L-741626 (12 µM); the selective D3 receptor antagonist SB 27701A (5 µM; Tocris); the selective D4 receptor antagonist L-745870 (5 µM; Tocris). We also used the α2 adrenergic receptor antagonist, yohimbine (2–4 µM; Tocris). Endogenous dopamine levels were manipulated with the DAT inhibitor GBR-12909 (10 µM; Hello Bio, Princeton, NJ) and the monoamine oxidase A and B inhibitor bifemelane (50 µM; Tocris).
+ Open protocol
+ Expand
10

Intraventricular L-745870 Dose Effect

Check if the same lab product or an alternative is used in the 5 most similar protocols
The L-745870 (D4R selective antagonist; Tocris Bioscience, UK) was used. The drug was initially prepared in a stock solution dissolved in 5% dimethyl sulfoxide (DMSO), and then dissolved in aliquots with sterile saline solution (0.9%). In a previous study performed in our laboratory, the intra-PVN administration of 0.1 µg of L-745870 prevented the PD-168,077-induced hyperfagia (Tejas-Juárez et al., 2014 (link)). Based on this evidence, we increased this dose 10-fold and 20-fold more to evaluate the intraventricular effect of the L-745870. The final concentrations infused in each experiment were 1-µg and 2-µg in a volume of 5 µl at a speed of 1 µl/min in the right lateral ventricle, using a high-precision digital syringe (Hamilton Co., Reno, NV). After administration, the microinjector remained 1-minute in the site to avoid backflow. Control animals received a volume of 5 µl of sterile saline 0.9% + 0.05% DMSO.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!